IM Cannabis Expands Leadership with Appointment of Alon Dayan to Board

IM Cannabis Expands Leadership with Alon Dayan

On January 5, 2026, IM Cannabis Corp. (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, announced the appointment of Alon Dayan to its Board of Directors. This strategic move is expected to bolster the company’s leadership team as it navigates the expanding landscape of the medicinal cannabis market.

A Proven Leader in Technology and Security

Alon Dayan has made a name for himself as the Chief Executive Officer of KeepZone AI Inc. His tenure with the company began in 2025, and he brings over 15 years of executive expertise, particularly within the homeland security technology realm. Dayan's accomplishments include the founding and scaling of innovative companies that specialize in systems integration, secure communications, and international business development.

Prior to his current role at KeepZone AI, Dayan was the founder and CEO of L1-Systems Ltd. since 2014. In this capacity, he managed complex solutions in homeland security and telecommunications and forged significant partnerships across various regions including Latin America and Eastern Europe. Furthermore, his previous experience as CEO of Virtual Crypto Technologies Inc. saw him lead product development and global sales for cryptocurrency ATMs, adding to his diverse skill set.

Dayan also held a critical role at Elbit Systems Ltd. as a Business Development Manager, where he oversaw defense electronics sales. His academic credentials include a Bachelor’s degree in Electrical and Electronic Engineering from Ariel University in Israel, solidifying his foundation in technology and engineering disciplines.

IM Cannabis: A Leader in Medical Cannabis

IM Cannabis Corp. is recognized for its international impact on the medical cannabis industry, providing high-quality cannabis products to patients in both Israel and Germany. With a focused strategy aimed at sustainable growth and profitability, the company operates within highly regulated environments while maintaining compliance and responsibility in all its ventures.

The company has developed an intricate transnational ecosystem that harnesses a data-driven approach to optimize their operations and enhance patient care. Through its subsidiaries, IM Cannabis imports and distributes medical cannabis in Israel and runs retail pharmacies and online platforms dedicated to delivering quality control and safe distribution of its products.

In Germany, the company operates through Adjupharm GmbH, serving pharmacies that supply medical cannabis to patients. Such extensive operations underline IM Cannabis’s commitment to growing its footprint in the global market while adhering to stringent regulations.

What This Means for IM Cannabis

Dayan's appointment to the board could signify a transformative era for IM Cannabis. His extensive background in technology and security may lead the company to explore innovative strategies, especially in operational efficiency and product development. These advancements can also support their efforts to amplify brand presence in competitive markets and improve internal processes.

As the medical cannabis sector continues to evolve, having leaders with a wealth of experience can help IM Cannabis navigate through emerging challenges while enhancing its growth trajectory. Dayan's experience and vision are poised to lead the company toward continued excellence and sustainable success.

With Dayan on board, stakeholders and investors will be keenly observing how his leadership will influence IM Cannabis’s strategies and performance in the coming years. The collective expertise of the board, now including Alon Dayan, represents a powerful asset as IM Cannabis aims to solidify its position as a global leader in the medical cannabis space.